- Posted By: TreehillPartners
- In: Strategy & Corporate Development
- Posted By: TreehillPartners
- In: Drug Development, Leadership & Restructuring, Strategy & Corporate Development
Abigail Beaney, author at Clinical Trials Arena, the flagship GlobalData publication, recently published an article featuring various perspectives on the funding situation of the biopharma
“The way to bring the NHS back to its former glory is to focus on driving efficiency” says Ali Pashazadeh, Treehill Partners CEO in a
“It is only by asking fundamental questions about the way we have done things in the past, understanding where the inefficiencies are, and how we
Scrip Asks… What Does 2025 Hold For Biopharma? Citeline flagship publication Scrip continues in its annual review series, where some of the most influential and
… could result in stronger, better funded, respected, and efficient global organisations. Ali Pashazadeh, Treehill Partners CEO, is quoted on Drug Discovery World examining the
… as Donald Trump takes up his presidency? The election outcome has certainly sparked more discussion than we typically see during an administration change. Traditionally,
Jon Smith, reporter at Mergermarket, has published Mergermarket’s European CNS market review featuring insights from Ali Pashazadeh, Treehill Partners CEO, including that “…a growing understanding
Scrip Asks… What Does 2025 Hold For Biopharma? Timely for this year’s J.P. Morgan conference, Citeline flagship publication Scrip continues in its annual review series
In this episode, BioSpace’s Head of Insights Lori Ellis, Miguel Forte and Ali Pashazadeh, Treehill Partners CEO, discuss the industry’s need to catch up with
Shani Alexander, journalist for BioWorld News, has published a larger article discussing the UK Government’s 10 year health plan to transform the UK’s National Health
